Lung Cancer Clinical Trial
Official title:
Pulmonary Artery Harmonic Ace+7 Energy Sealing in Open Lobectomy Human Pilot Study
VATS anatomical lung resection provides an effective minimally invasive treatment strategy
for stage I and II lung cancer. VATS lobectomy is associated with significantly less
postoperative atrial fibrillation, blood transfusion, renal failure, and other complications
when compared with lobectomy via thoracotomy.
Although VATS lobectomy has been proven to be effective and safe in experienced hands, it is
not devoid of risk. Intra-operative surgical complications can be at times catastrophic.
Complications include: pulmonary vascular injuries (PA, pulmonary vein) necessitating urgent
conversion to open thoracotomy and even death14. Causes of conversion included PA injury,
difficult anatomy, bulky/calcified lymph nodes, and technical problems including stapler
misfire. PA injury alone constituted 37.5% of all conversions. Proper dissection of all
tissue around PA branches is sometime difficult especially in the presence of adhesions or
large, calcified lymph nodes and may increase the risk of vascular injury.
Currently, in spite of being a safe and effective technique in experienced hands, a minority
of anatomical pulmonary resections are being performed by VATS. In an analysis utilizing the
Nationwide Inpatient Sample (NIS) database in the United States, only 15% of anatomical lung
resections were performed by VATS.
The technical difficulty and danger of VATS lobectomy is directly related to PA branch
manipulation, stapling and division. PA manipulation is the main hesitation of many thoracic
surgeons regarding the adoption of VATS lobectomy. The investigators believe that by
decreasing the manipulation and dissection required by the surgeon on the PA branches, these
procedures will be safe and therefore more prevalent for anatomical pulmonary resections.
Status | Completed |
Enrollment | 10 |
Est. completion date | October 2015 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - All patients planned to undergo an open lobectomy at the CHUM-Hôpital Notre-Dame Exclusion Criteria: - Age < 18 years old - Inability to consent to the study |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Centre Hospitalier de l'Université de Montréal | Montréal | Quebec |
Lead Sponsor | Collaborator |
---|---|
Centre hospitalier de l'Université de Montréal (CHUM) | Centre de Recherche du Centre Hospitalier de l'Université de Montréal |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Effective intra-operative pulmonary arterial branch vessel sealing measured by presence or lack of vessel sealing failure (binary outcome: yes/no). | In this first human trial, we will only recruit patients scheduled to undergo an open lobectomy for safety issues. If bleeding occurs due to seal failure, bleeding control and vessel repair is technically easier though a thoracotomy incision than by VATS. All patients will have 4-0 prolene with SH needle ready for use on the sterile field in case there is a sealing failure that needs to be fixed. Additionnaly, all patients are routinely crossmatched for 2 units of packed red blood cells (as per standard pre-operative orders). All cases will be videotaped with a thoracosocpic 10 mm, 30 degree camera placed through the chest tube insertion site in order to evaluate the problems in cases of seal failure. Additionnaly, all patients are routinely crossmatched for 2 units of packed red blood cells (as per standard pre-operative orders). |
30 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|